What Эуфиллин-Эском Treats: Main Uses and Benefits

This medication is generally used to help address the symptoms related to physical discomfort from acute airway obstruction. It is applied across domains where additional symptomatic support is needed in conditions including asthma, chronic bronchitis, and emphysema. This is relevant for easing symptom clusters such as wheezing, shortness of breath, and difficulty breathing when they intensify temporarily.

This medication is commonly used when short-term symptomatic assistance is needed in clinical settings involving acute or unstable symptom patterns, such as during severe acute exacerbations. The therapeutic benefit is supportive relief from bronchospasm, which contributes to improved air exchange and assists with managing the sudden discomfort associated with respiratory distress.

“The primary goal is providing supportive assistance to help maintain a sense of stability during a severe episode.”

It may also be part of symptomatic management for specific pathological breathing patterns, supporting general well-being during symptomatic phases.

---

Quick Fact: Relief for Acute Respiratory Distress

Parameter	Use Context
Symptom Category	Acute Airway Constriction Symptoms
Applicable Conditions	Conditions involving episodic or fluctuating manifestations (e.g., Asthma)
Patient Benefit	Supports maintenance of stable breathing function
Use Scenario	Applied during phases when symptoms become more noticeable

Regulatory References

1. NIH MedlinePlus overview of Aminophylline

Who Can and Cannot Use Эуфиллин-Эском? (Official Regulatory Information)

The official eligibility for Эуфиллин-Эском (Aminophylline injection) is strictly defined by regulatory documents, which establish groups who must not use the medicine and those for whom use is restricted.

Absolute Contraindications

This medication is strictly contraindicated in patients with a known hypersensitivity to any xanthine derivative (e.g., theophylline, caffeine) or the component ethylenediamine. Absolute exclusion criteria also include severe cardiac conditions like tachyarrhythmias, acute conditions like hemorrhagic stroke, retinal hemorrhage, and active peptic ulcer disease. For certain regional IV formulations, the medicine is contraindicated in children younger than 3 years.

Populations Requiring Caution and Restriction ️

Use is highly restricted and requires caution in several populations due to the risk of toxicity or reduced drug clearance:

Population/Condition	Regulatory Status (Use With Caution Only)
Hepatic or Severe Renal Dysfunction	Restricted use due to significantly decreased clearance.
Cardiopulmonary Conditions	Congestive heart failure (CHF) and acute febrile illness.
Age Groups	Elderly patients (>60 years) and infants (under 1 year).
Pregnancy/Lactation	Pregnancy Category C; use during lactation is often contraindicated.

These rules formally dictate who is eligible and ineligible for treatment, based on the patient's existing health status, organ function, or age.

Interactions with other medicines and products

This section describes officially documented interaction patterns for Эуфиллин-Эском (Aminophylline), which are categorized by government regulatory authorities.

---

Formal Prohibition and Restrictions

Co-administration with other xanthine derivatives, including the active component Theophylline or related drugs such as Pentoxifylline, is formally prohibited due to the hazard of severe, additive toxicity. Use is also restricted in patients with Acute Porphyria or known hypersensitivity to the Ethylenediamine component.

---

Pharmacokinetic Clearance Modifiers

Interactions that alter the clearance (elimination) of the drug's active substance are documented. Substances that decrease clearance (increasing plasma concentrations) include the antibiotics Ciprofloxacin and Erythromycin, Cimetidine, and Fluvoxamine. Conversely, substances that increase clearance (decreasing plasma concentrations) include Rifampicin and the antiepileptics Phenytoin and Carbamazepine.

---

Pharmacodynamic and Substance Interactions

Interactions that cause additive functional effects are documented. Combining the medicine with Beta-2 Adrenergic Agonists or Corticosteroids increases the risk of hypokalaemia. The herbal product St John's Wort is documented to decrease plasma concentrations. Additionally, caffeine may contribute to additive central nervous system (CNS) stimulant effects.

---

Population-Specific Notes

The clearance of the drug is officially documented as reduced in elderly patients, infants (under 1 year), and those with hepatic dysfunction, increasing the potential for interaction-related toxicity in these populations.

How Эуфиллин-Эском Works

Эуфиллин-Эском acts via its active metabolite, theophylline, which utilizes three distinct molecular mechanisms to modulate respiratory function. The primary action is the non-selective competitive inhibition of Phosphodiesterase (PDE) enzymes, particularly the PDE3 and PDE4 subtypes, within bronchial smooth muscle cells. Blocking PDE prevents the degradation of the intracellular messenger cAMP, causing its concentration to rise. This cascade leads to the sequestration of calcium ions, which is the direct molecular trigger for the relaxation of bronchial smooth muscle, thereby altering the diameter of the airways.

Theophylline also functions as a non-selective antagonist of adenosine receptors. By occupying these receptors, the drug blocks signaling by endogenous adenosine, a molecule that promotes bronchoconstriction and inflammatory mediator release. This antagonism modulates the cellular processes that contribute to excessive airway reactivity.

Furthermore, theophylline contributes to the anti-inflammatory effect profile by restoring the function of Histone Deacetylase 2 (HDAC2), an enzyme essential for suppressing the transcription of pro-inflammatory genes driven by factors like NF-kappaB, thus modulating the magnitude of airway inflammation.

How to Use Эуфиллин-Эском

Эуфиллин-Эском, which contains the active ingredient aminophylline, is strictly administered via slow intravenous (IV) infusion or injection. The administration is a highly controlled, two-stage process typically reserved for supervised settings. The drug is not recommended for intramuscular (IM) use due to the risk of severe local effects.

---

Dosing and Administration Protocol

The standard protocol for use begins with a Loading Dose followed by a continuous Maintenance Infusion to sustain the necessary therapeutic concentration.

Procedural Requirement	Standard Instruction
Dose Calculation Basis	Must be based on the patient's Ideal Body Weight (IBW), not actual body weight, to prevent overdose.
Initial Rate Constraint	The rate of injection or infusion for the loading dose must not exceed 25 mg/minute to control drug concentration in the circulation.
Preparation	The solution must be diluted in compatible intravenous fluids, such as 5% Dextrose or 0.9% Sodium Chloride, prior to infusion.
Monitoring	Mandatory and frequent monitoring of the serum theophylline concentration is required to adjust the subsequent maintenance dose rate.

---

Population-Specific Use Adjustments

Standard prescribing guidelines indicate that the maintenance infusion rate must be significantly reduced for certain patient populations, including older adults (typically defined as over 55 years) and patients with hepatic impairment or heart failure. These adjustments are essential due to altered drug clearance in these groups.

Overview of Clinical Studies

Эуфиллин-Эском contains the active ingredient aminophylline, which is a complex of theophylline and ethylenediamine. The clinical research base for this drug focuses on the effects of theophylline in managing obstructive airway diseases, primarily asthma and Chronic Obstructive Pulmonary Disease (COPD). Theophylline is generally considered a third-line or add-on therapy in regions with widespread access to inhaled corticosteroids and beta2-agonists, due to its narrow therapeutic window.

Studies have assessed the drug's role in individuals whose conditions are not adequately controlled by standard inhaled therapies. Research findings suggest theophylline may provide two main types of benefit:

• Bronchodilation: An effect observed at a higher range of plasma concentrations, where it helps relax the smooth muscles of the airways, potentially improving lung function (e.g., Forced Expiratory Volume in 1 second or FEV1).
• Anti-inflammatory Effects: Research, particularly at lower concentrations, has investigated theophylline's potential to influence inflammatory processes in the airways. One area of focus is on its possible ability to restore or enhance the anti-inflammatory effects of corticosteroids in patients with severe asthma or COPD.

Combination Therapy Research

In COPD, clinical trials have explored whether adding low-dose theophylline to inhaled corticosteroids and long-acting bronchodilators reduces the frequency of acute exacerbations. Results in this area have been mixed. Some large randomized trials found that the addition of low-dose theophylline did not significantly reduce the overall rate of exacerbations compared to placebo, though some post-hoc analyses suggested a potential reduction in the rate of severe (hospitalized) exacerbations. Researchers continue to examine the exact role of theophylline in combination with other modern therapies.

Common questions about Эуфиллин-Эском (FAQ)

Q: Is Эуфиллин-Эском used for long-term control or for short-term breathing relief?

A: According to official product information, Эуфиллин-Эском (Aminophylline) is a bronchodilator primarily indicated for the treatment of acute exacerbations of bronchial asthma and COPD. Regulatory documents describe its use in a supervised setting for short-term, acute exacerbations when patients have not adequately responded to initial treatments.

Q: Is Эуфиллин-Эском considered a rescue medication for acute attacks?

A: The medicine is indicated for use in acute attacks of severe respiratory disease and is administered via intravenous (IV) infusion to provide rapid relief. While the term 'rescue medication' is often reserved for inhaled treatments, the drug’s use in acute settings is consistent with providing rapid relief for severe airway obstruction.

Q: What types of over-the-counter cold medicines or supplements might interact with Эуфиллин-Эском?

A: Regulatory documents state that caution is needed when combining this medicine with Beta-2 Adrenergic Agonists, which are common components in some cold medicines. Additionally, official warnings note a risk of increased Central Nervous System (CNS) stimulation if it is combined with high amounts of caffeine from supplements or other products.

Q: What is the difference between oral tablets and intravenous (IV) injection forms of the medicine contained in Эуфиллин-Эском?

A: The Intravenous (IV) injection form of the medicine is a solution designed for rapid introduction of the drug into the bloodstream, making it suitable for treating severe, acute conditions in a hospital setting. Oral forms, which may exist under a different name, are generally described as being suitable for chronic or longer-term management.

Q: Is Эуфиллин-Эском used for coughs, or only for deeper breathing difficulties?

A: Official information indicates that the active ingredient is a bronchodilator intended to relax the muscles in the air passages of the lungs. Its stated purpose is to relieve symptoms such as cough, wheezing, shortness of breath, and troubled breathing by helping to increase airflow.

Q: Why does Эуфиллин-Эском sometimes cause nervousness or anxiety?

A: Nervousness, anxiety, and restlessness are listed as documented side effects of the medicine. These effects relate to the drug's action in the body, which involves stimulating the central nervous system (CNS).

Q: Can Эуфиллин-Эском cause issues with sleep or insomnia?

A: According to official product information, trouble sleeping and insomnia are documented side effects of this medication. These potential effects on sleep patterns are documented in the official product information.

Q: Does smoking tobacco affect how quickly the body processes Эуфиллин-Эском?

A: Yes, regulatory documents clearly state that tobacco smoking and smoking cessation can affect the drug's clearance. This may lead to changes in drug clearance that affect the required therapeutic blood levels.

Q: Is the consumption of alcohol generally advised against while using Эуфиллин-Эском?

A: Official documentation states that drinking alcohol while using this medicine is generally restricted. This restriction is noted because alcohol may interfere with how the drug works and potentially worsen certain side effects.

Q: Can major changes in diet affect the level of Эуфиллин-Эском in the bloodstream?

A: Yes, official guidance documents describe the need for major changes in diet to be noted, as certain dietary habits can alter the amount of the drug in the bloodstream. This caution is often specific to significant fluctuations in caffeine intake.

Q: Is it true that smoking marijuana can also affect the metabolism of Эуфиллин-Эском?

A: Official sources note that marijuana smoking may interfere with the metabolism and affect how the medicine works.

Q: How quickly does the therapeutic effect of Эуфиллин-Эском typically begin after taking it?

A: The medicine is administered via slow intravenous infusion, which is a rapid delivery method. The initial Loading Dose is intended to quickly achieve a therapeutic concentration in the blood, indicating a fast onset of action when compared to oral forms.

Q: How long do the beneficial effects of Эуфиллин-Эском generally last in the body?

A: The effects of the intravenous solution are maintained by a continuous Maintenance Infusion that follows the initial dose. This administration process is designed to keep the drug level constant in the blood over the duration of the treatment.

Q: Why is consistency in the daily administration time so important for Эуфиллин-Эском?

A: Official proper use guidance emphasizes that a constant amount of the drug in the blood is required for the intended therapeutic effect. For chronic forms, taking the medicine at the same time each day helps maintain this necessary steady blood level.

Q: Does the active component of Эуфиллин-Эском have an effect on urine volume, such as diuresis?

A: Yes, regulatory sources list an increase in urine volume (known as diuresis) as a documented effect of the active component of this medication.

Q: What is the described role of Эуфиллин-Эском in treating breathing issues in premature infants?

A: The active ingredient, theophylline, has a documented role in the clinical management of Neonatal Apnea (recurrent episodes of pauses in breathing) in premature infants.

Q: Is the medication contained in Эуфиллин-Эском officially documented as a diuretic agent?

A: While the drug is primarily classified as a bronchodilator, official regulatory documents confirm that the active substance can cause diuresis, which is an increase in urine volume, as a known effect.

Q: Are there any known interactions between Эуфиллин-Эском and common seasonal flu vaccines?

A: Some regulatory-referenced literature notes that certain vaccinations, including the influenza vaccine, may reduce the clearance (elimination) of the drug from the body. This potential interaction may affect the drug's clearance, which could alter therapeutic blood levels.

Q: If I feel better, is it necessary to continue taking Эуфиллин-Эском?

A: Official proper use guidance states that discontinuing the medicine or changing the dosage is not advised, even if improvement is noted, without consulting a healthcare professional.

Storage and Disposal Requirements for Эуфиллин-Эском (Aminophylline Injection)

This medication must be stored according to official regulatory specifications to maintain its quality and stability.

---

Storage Conditions

Requirement	Official Specification
Temperature	Store at Controlled Room Temperature, 20 C to 25 C, with temporary excursions permitted.
Protection	Keep the container tightly sealed and protect from light.
Child Safety	The product must be stored locked up or secured from unauthorized access.
Stability	As a single-dose injection, any unused portion must be discarded.

---

Disposal Instructions

Unused or expired product must be disposed of in compliance with regulatory rules. The contents and container must be taken to an approved waste disposal plant and should not be released into the environment or empty into drains.